AUROBINDO

June 14, 2022

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions for the half year ended March 31, 2022

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended March 31, 2022.

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B.Adi Reddy
Company Secretary

Encl: as above.

AUROBINDO PHARMA LIMITED

Disclosure of related party transactions for the half year ended 31st March 2022

Sl. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
											In case any financial indebtedness is incurred to make or give loans, inter- corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN (Please refer Note No.3	Name	PAN (Please refer Note No.3	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be
1	Aurobindo Pharma Limited		Pravesha Industries Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	3500.0	1683.9	-	-	-	-	-	-	-	-	-	-
2	Aurobindo Pharma Limited		Pravesha Industries Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	2.0	0.6	-	-	-	-	-	-	-	-	-	-
3	Aurobindo Pharma Limited		Pravesha Industries Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of fixed assets	2.5	2.5	-	-	-	-	-	-	-	-	-	-
4	Aurobindo Pharma Limited		Pravesha Industries Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	997.2	-	-	-	-	-	-	-	-	-	-
5	Aurobindo Pharma Limited		Sri Sai Packaging, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	280.0	150.3	-	-	-	-	-	-	-	-	-	-
6	Aurobindo Pharma Limited		Sri Sai Packaging, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	0.7	0.3	-	-	-	-	-	-	-	-	-	-
7	Aurobindo Pharma Limited		Sri Sai Packaging, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	39.5	-	-	-	-	-	-	-	-	-	-
8	Aurobindo Pharma Limited		Trident Chemphar Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	1300.0	471.8	-	-	-	-	-	-	-	-	-	-
9	Aurobindo Pharma Limited		Trident Chemphar Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	NA	-22.3	-	-	-	-	-	-	-	-	-	-
10	Aurobindo Pharma Limited		Trident Chemphar Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Dividend paid	Refer Note 2	2.4	-	-	-	-	-	-	-	-	-	-
11	Aurobindo Pharma Limited		Trident Chemphar Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	53.7	-	-	-	-	-	-	-	-	-	-
12	Aurobindo Pharma Limited		Axis Clinicals Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	2000.0	869.0	-	-	-	-	-	-	-	-	-	-
13	Aurobindo Pharma Limited		Axis Clinicals Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Dividend paid	Refer Note 2	2.0	-	-	-	-	-	-	-	-	-	-
14	Aurobindo Pharma Limited		Axis Clinicals Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	476.1	-	-	-	-	-	-	-	-	-	-
15	Aurobindo Pharma Limited		Pranit Packaging Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	300.0	132.1	-	-	-	-	-	-	-	-	-	-
16	Aurobindo Pharma Limited		Pranit Packaging Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	35.4	-	-	-	-	-	-	-	-	-	-
17	Aurobindo Pharma Limited		SGD Pharma India Limited (formerly Cogent Glass Limited), India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	1250.0	431.8	-	-	-	-	-	-	-	-	-	-



AUROBINDO PHARMA LIMITED

Disclosure of related party transactions for the half year ended 31st March 2022

													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
18	Aurobindo Pharma Limited		SGD Pharma India Limited (formerly Cogent Glass Limited), India		Enterprises over which key management personnel or their relatives exercise significant influence	Reimbursement of expenses received	NA	1.6	-	-	-	-	-	-	-	-	-	-	-
19	Aurobindo Pharma Limited		SGD Pharma India Limited (formerly Cogent Glass Limited), India		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	3.0	1.2	-	-	-	-	-	-	-	-	-	-	-
20	Aurobindo Pharma Limited		SGD Pharma India Limited (formerly Cogent Glass Limited), India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	314.3	-	-	-	-	-	-	-	-	-	-	-
21	Aurobindo Pharma Limited		Orem Access Bio Inc, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	400.0	111.9	-	-	-	-	-	-	-	-	-	-	-
22	Aurobindo Pharma Limited		Orem Access Bio Inc, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	46.9	-	-	-	-	-	-	-	-	-	-	-
23	Aurobindo Pharma Limited		Veritaz Healthcare Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Rent received	0.4	0.4	-	-	-	-	-	-	-	-	-	-	-
24	Aurobindo Pharma Limited		Veritaz Healthcare Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	450	153.2	-	-	-	-	-	-	-	-	-	-	-
25	Aurobindo Pharma Limited		Veritaz Healthcare Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance receivable	NA	159.6	-	-	-	-	-	-	-	-	-	-	-
26	Aurobindo Pharma Limited		Axis Clinicals LLC, USA		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	NA	189.3	-	-	-	-	-	-	-	-	-	-	-
27	Aurobindo Pharma Limited		Axis Clinicals LLC, USA		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	86.2	-	-	-	-	-	-	-	-	-	-	-
28	Aurobindo Pharma Limited		Crest Cellulose Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	400.0	114.0	-	-	-	-	-	-	-	-	-	-	-
29	Aurobindo Pharma Limited		Crest Cellulose Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	61.3	-	-	-	-	-	-	-	-	-	-	-
30	Aurobindo Pharma Limited		East Pharma Technologies, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	120	54.4	-	-	-	-	-	-	-	-	-	-	-
31	Aurobindo Pharma Limited		East Pharma Technologies, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of services	0.2	0.1	-	-	-	-	-	-	-	-	-	-	-
32	Aurobindo Pharma Limited		East Pharma Technologies, India (Partnership firm)		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	23.8	-	-	-	-	-	-	-	-	-	-	-
33	Aurobindo Pharma Limited		Axis Clinicals Latina SA DE CV, Mexico		Enterprises over which key management personnel or their relatives exercise significant influence	purchase of services	34.0	11.5	-	-	-	-	-	-	-	-	-	-	-
34	Aurobindo Pharma Limited		Axis Clinicals Latina SA DE CV, Mexico		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	4.9	-	-	-	-	-	-	-	-	-	-	-
35	Aurobindo Pharma Limited		Gelcaps Industries, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchases	550.0	324.0	-	-	-	-	-	-	-	-	-	-	-



AUROBINDO PHARMA LIMITED

Disclosure of related party transactions for the half year ended 31st March 2022

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
36	Aurobindo Pharma Limited		Gelcaps Industries, India		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	NA	0.5	-	-	-	-	-	-	-	-	-	-
37	Aurobindo Pharma Limited		Gelcaps Industries, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	139.0	-	-	-	-	-	-	-	-	-	-
38	Aurobindo Pharma Limited		Alcedo Pharmachem Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	purchases	330.0	153.0	-	-	-	-	-	-	-	-	-	-
39	Aurobindo Pharma Limited		Alcedo Pharmachem Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	19.7	-	-	-	-	-	-	-	-	-	-
40	Aurobindo Pharma Limited		Ambipack Industries, India		Enterprises over which key management personnel or their relatives exercise significant influence	purchases	165.0	67.9	-	-	-	-	-	-	-	-	-	-
41	Aurobindo Pharma Limited		Ambipack Industries, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	22.4	-	-	-	-	-	-	-	-	-	-
42	Aurobindo Pharma Limited		Giyaan Pharma Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Sale of products	40.0	19.2	-	-	-	-	-	-	-	-	-	-
43	Aurobindo Pharma Limited		Giyaan Pharma Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance receivable	NA	34.2	-	-	-	-	-	-	-	-	-	-
44	Aurobindo Pharma Limited		Aurobindo Realty & Infrastructure Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of capital goods	600.0	119.2	-	-	-	-	-	-	-	-	-	-
45	Aurobindo Pharma Limited		Aurobindo Realty & Infrastructure Private Limited, India		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	75.3	-	-	-	-	-	-	-	-	-	-
46	Aurobindo Pharma Limited		Aurobindo Pharma Foundation (SEC 8 Company), India		Enterprises over which key management personnel or their relatives exercise significant influence	Contribution towards CSR activities	NA	380.0	-	-	-	-	-	-	-	-	-	-
47	Aurobindo Pharma Limited		KAKINADA SEZ LIMITED		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of fixed assets	290.0	1121.1	-	-	-	-	-	-	-	-	-	-
48	Aurobindo Pharma Limited		Sportz & Live Entertainment Private Limited		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	0.5	0.2	-	-	-	-	-	-	-	-	-	-
49	Aurobindo Pharma Limited		Transaction Square LLP		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	4.0	2.1	-	-	-	-	-	-	-	-	-	-
50	Aurobindo Pharma Limited		Transaction Square LLP		Enterprises over which key management personnel or their relatives exercise significant influence	Balance payable	NA	0.1	-	-	-	-	-	-	-	-	-	-
51	Aurobindo Pharma Limited		Zoylo Digihealth Private Limited		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	1.5	0.7	-	-	-	-	-	-	-	-	-	-
52	Aurobindo Pharma Limited		Sathguru Software Products Pvt Ltd		Enterprises over which key management personnel or their relatives exercise significant influence	Purchase of services	5.0	5.9	-	-	-	-	-	-	-	-	-	-
53	Aurobindo Pharma Limited		NVNR (Ramannapet I) Power Plant Private Limited, India		Associate	Equity contribution	5.2	5.2	-	-	-	-	-	-	-	-	-	-
54	Aurobindo Pharma Limited		NVNR (Ramannapet I) Power Plant Private Limited, India		Associate	Investment in Optionally Convertible Debentures	48.6	48.6	-	-	-	-	-	-	-	-	-	-



AUROBINDO PHARMA LIMITED

Disclosure of related party transactions for the half year ended 31st March 2022

													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
55	Aurobindo Pharma Limited		NVNR (Ramannapet II) Power Plant Private Limited, India		Associate	Equity contribution	5.2	5.2	-	-	-	-	-	-	-	-	-	-	-
56	Aurobindo Pharma Limited		NVNR (Ramannapet II) Power Plant Private Limited, India		Associate	Investment in Optionally Convertible Debentures	48.6	48.6	-	-	-	-	-	-	-	-	-	-	-
57	Aurobindo Pharma Limited		Novagen Pharma (Pty) Limited, South Africa		Joint ventures	Sale of products	NA	62.2	-	-	-	-	-	-	-	-	-	-	-
58	Aurobindo Pharma Limited		Novagen Pharma (Pty) Limited, South Africa		Joint ventures	Sale of services	NA	17.8	-	-	-	-	-	-	-	-	-	-	-
59	Aurobindo Pharma Limited		Novagen Pharma (Pty) Limited, South Africa		Joint ventures	Balance receivable	NA	57.4	-	-	-	-	-	-	-	-	-	-	-
60	Aurobindo Pharma Limited		Novagen Pharma (Pty) Limited, South Africa		Joint ventures	Dividend receivable	NA	357.0			-	-	-	-	-	-	-	-	-
61	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Interest accrued	NA	50.4	-	-	-	-	-	-	-	-	-	-	-
62	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Investment in Optionally Convertible Debenture	500	500.0	-	-	-	-	-	-	-	-	-	-	-
63	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Reimbursement of expenses received	NA	0.5	-	-	-	-	-	-	-	-	-	-	-
64	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Rent expenses including maintenance	250.0	150.2	-	-	-	-	-	-	-	-	-	-	-
65	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Balance payable	NA	7.4	-	-	-	-	-	-	-	-	-	-	-
66	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Balance receivable	NA	47.8	-	-	-	-	-	-	-	-	-	-	-
67	Aurobindo Pharma Limited		Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)		Joint ventures	Rent deposit receivable	120.0	100.8	-	-	-	-	-	-	-	-	-	-	-
68	Aurobindo Pharma Limited		Tergene Biotech Private Limited, India		Joint ventures	Investment in 10.5% cumulative redeemable preference shares	400.0	37.0	-	-	-	-	-	-	-	-	-	-	-
69	Aurobindo Pharma Limited		Purple Bellflower (Pty)Ltd, South Africa		Joint ventures	Dividend received	NA	2.8	-	-	-	-	-	-	-	-	-	-	-
70	Aurobindo Pharma Limited		Purple Bellflower (Pty)Ltd, South Africa		Joint ventures	Loans and advances given	NA	0.2	-	-	-	-	-	-	-	-	-	-	-
71	Aurobindo Pharma Limited		Purple Bellflower (Pty)Ltd, South Africa		Joint ventures	Balance receivable	NA	3.1	-	-	-	-	-	-	-	-	-	-	-
72	Aurobindo Pharma Limited		Luoxin Aurovitas Pharma(Chengdu) Co.,LTD		Joint ventures	Sale of service	NA	313.9	-	-	-	-	-	-	-	-	-	-	-
73	Aurobindo Pharma Limited		Luoxin Aurovitas Pharma(Chengdu) Co.,LTD		Joint ventures	Equity contribution	NA	154.8	-	-	-	-	-	-	-	-	-	-	-
74	Aurobindo Pharma Limited		Luoxin Aurovitas Pharma(Chengdu) Co.,LTD		Joint ventures	Balance receivable	NA	317.4	-	-	-	-	-	-	-	-	-	-	-
75	Aurobindo Pharma Limited		Mr. K. Nityananda Reddy, Whole-time Director		Key managerial personnel	Rent expenses (Receiving of services)	2.4	1.5	-	-	-	-	-	-	-	-	-	-	-
76	Aurobindo Pharma Limited		Mr. K. Nityananda Reddy, Whole-time Director		Key managerial personnel	Remuneration	Refer Note 2	16.0	-	-	-	-	-	-	-	-	-	-	-
77	Aurobindo Pharma Limited		Mr. K. Nityananda Reddy, Whole-time Director		Key managerial personnel	Dividend paid	Refer Note 2	76.1	-	-	-	-	-	-	-	-	-	-	-
78	Aurobindo Pharma Limited		Dr. M. Sivakumaran, Whole-time Director		Key managerial personnel	Remuneration	Refer Note 2	12.1	-	-	-	-	-	-	-	-	-	-	-
79	Aurobindo Pharma Limited		Dr. M. Sivakumaran, Whole-time Director		Key managerial personnel	Dividend paid	Refer Note 2	43.5	-	-	-	-	-	-	-	-	-	-	-
80	Aurobindo Pharma Limited		Mr. M. Madan Mohan Reddy, Whole-time Director		Key managerial personnel	Remuneration	Refer Note 2	27.2	-	-	-	-	-	-	-	-	-	-	-
81	Aurobindo Pharma Limited		Mr. P. Sarath Chandra Reddy, Whole-time Director		Key managerial personnel	Remuneration	Refer Note 2	7.6	-	-	-	-	-	-	-	-	-	-	-
82	Aurobindo Pharma Limited		Mr. N. Govindarajan, Managing Director		Key managerial personnel	Remuneration	Refer Note 2	22.7	-	-	-	-	-	-	-	-	-	-	-
83	Aurobindo Pharma Limited		Mr. N. Govindarajan, Managing Director		Key managerial personnel	Commission	Refer Note 2	62.5	-	-	-	-	-	-	-	-	-	-	-
84	Aurobindo Pharma Limited		Mr. N. Govindarajan, Managing Director		Key managerial personnel	Post employment benefits	Refer Note 2	3.0	-	-	-	-	-	-	-	-	-	-	-
85	Aurobindo Pharma Limited		Mr. N. Govindarajan, Managing Director		Key managerial personnel	Balance payable	NA	62.5	-	-	-	-	-	-	-	-	-	-	-
86	Aurobindo Pharma Limited		Mr. Santhanam Subramanian, Chief Financial Officer		Key managerial personnel	Remuneration	Refer Note 2	17.6	-	-	-	-	-	-	-	-	-	-	-
87	Aurobindo Pharma Limited		Mr. Santhanam Subramanian, Chief Financial Officer		Key managerial personnel	Post employment benefits	Refer Note 2	2.0	-	-	-	-	-	-	-	-	-	-	-
88	Aurobindo Pharma Limited		Mr. B. Adi Reddy, Company Secretary		Key managerial personnel	Remuneration	Refer Note 2	3.6	-	-	-	-	-	-	-	-	-	-	-
89	Aurobindo Pharma Limited		Mr. B. Adi Reddy, Company Secretary		Key managerial personnel	Post employment benefits	Refer Note 2	0.3	-	-	-	-	-	-	-	-	-	-	-



AUROBINDO PHARMA LIMITED

Disclosure of related party transactions for the half year ended 31st March 2022

																			Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
90	Aurobindo Pharma Limited		Mr. K. Ragunathan, Non-executive Chairman and Independent Director		Key managerial personnel	Director sitting fee	Refer Note 2	3.1	-	-	-	-	-	-	-	-	-	-	-
91	Aurobindo Pharma Limited		Dr. (Mrs.) Avnit Bimal Singh, Independent Director		Key managerial personnel	Director sitting fee	Refer Note 2	2.1	-	-	-	-	-	-	-	-	-	-	-
92	Aurobindo Pharma Limited		Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director		Key managerial personnel	Remuneration	Refer Note 2	12.7	-	-	-	-	-	-	-	-	-	-	-
93	Aurobindo Pharma Limited		Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director		Key managerial personnel	Director sitting fee	Refer Note 2	0.9	-	-	-	-	-	-	-	-	-	-	-
94	Aurobindo Pharma Limited		Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director		Key managerial personnel	Dividend paid	Refer Note 2	54.0	-	-	-	-	-	-	-	-	-	-	-
95	Aurobindo Pharma Limited		Mrs.Savitha Mahajan, Independent Director		Key managerial personnel	Director sitting fee	Refer Note 2	2.6	-	-	-	-	-	-	-	-	-	-	-
96	Aurobindo Pharma Limited		Mr.Girish Paman Vanvari, Independent Director		Key managerial personnel	Director sitting fee	Refer Note 2	3.1	-	-	-	-	-	-	-	-	-	-	-
97	Aurobindo Pharma Limited		Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)		Relative of Key managerial personnel	Remuneration	Refer Note 2	3.8	-	-	-	-	-	-	-	-	-	-	-
98	Aurobindo Pharma Limited		Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)		Relative of Key managerial personnel	Post employment benefits	Refer Note 2	0.4	-	-	-	-	-	-	-	-	-	-	-
99	Aurobindo Pharma Limited		RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI		Promoter group	Dividend paid	Refer Note 2	589.1	-	-	-	-	-	-	-	-	-	-	-
100	Aurobindo Pharma Limited		AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING)		Promoter group	Dividend paid	Refer Note 2	50.2	-	-	-	-	-	-	-	-	-	-	-
101	Aurobindo Pharma Limited		SUNEELA RANI PENAKA		Promoter group	Dividend paid	Refer Note 2	0.4	-	-	-	-	-	-	-	-	-	-	-
102	Aurobindo Pharma Limited		K RAJESWARI		Promoter group	Dividend paid	Refer Note 2	5.5	-	-	-	-	-	-	-	-	-	-	-
103	Aurobindo Pharma Limited		PRASADA REDDY KAMBHAM		Promoter group	Dividend paid	Refer Note 2	1.0	-	-	-	-	-	-	-	-	-	-	-
104	Aurobindo Pharma Limited		K SURYAPRAKASH REDDY		Promoter group	Dividend paid	Refer Note 2	0.0	-	-	-	-	-	-	-	-	-	-	-
105	Aurobindo Pharma Limited		M SUMANTH KUMAR REDDY		Promoter group	Dividend paid	Refer Note 2	4.8	-	-	-	-	-	-	-	-	-	-	-
106	Aurobindo Pharma Limited		KIRTHI REDDY KAMBAM		Promoter group	Dividend paid	Refer Note 2	61.3	-	-	-	-	-	-	-	-	-	-	-
107	Aurobindo Pharma Limited		KAMBAM SPOORTHI		Promoter group	Dividend paid	Refer Note 2	21.0	-	-	-	-	-	-	-	-	-	-	-

Note: 1. The value of the related party transaction denotes the amount approved by the Audit Committee / Board of Directors of Aurobindo Pharma Limited for the financial year 2021-22
2. As per the approval of Board of Directors / Shareholders as necessary
3. Since RPT disclosure is filing in Pdf format the PAN details are not included in the disclosure.

For AUROBINDO PHARMA LIMITED

B.ADI REDDY
Company Secretary